Neratinib Nerlynx Drug International Pharma

Product Name: Neratinib

English Name: Neratinib

Specification: 40 mg × 30 tablets/box

Manufacturer: Drug International Pharma

Neratinib is an oral, irreversible tyrosine kinase inhibitor. It is the only product globally approved for extended adjuvant therapy following trastuzumab (Herceptin) treatment for HER2-positive breast cancer, serving to reduce the risk of disease recurrence. It is indicated for patients who have completed standard trastuzumab adjuvant therapy without disease progression but who possess high-risk factors.

Following chemotherapy and trastuzumab treatment, the administration of Neratinib as extended adjuvant therapy can significantly reduce the rate of clinically meaningful breast cancer recurrences—specifically, recurrences that may lead to death (e.g., distant metastases and local recurrences outside the conserved breast)—without increasing the risk of long-term toxicity.

Currently, in the treatment of HER2-positive breast cancer, adjuvant therapy involving chemotherapy combined with or sequenced after trastuzumab constitutes the standard of care. However, patients may still experience recurrence after discontinuing trastuzumab treatment; the likelihood of recurrence is highest during the period spanning from the last six months of the one-year trastuzumab regimen to one year after its completion. Approved by the U.S. FDA in July 2017, Neratinib addresses the urgent need for new therapeutic options to reduce the risk of recurrence in early-stage HER2-positive breast cancer.

Neratinib possesses a broad yet specific spectrum of therapeutic targets, acting against HER1, HER2, and HER4. Among currently available HER2-targeted agents, it targets the widest range of receptors. Consequently, Neratinib-based therapy remains a viable option even in cases where resistance has developed against trastuzumab, pertuzumab, T-DM1, or lapatinib.

Even in the presence of HER2 point mutations, the use of Neratinib can still yield favorable therapeutic outcomes. In addition to gene amplification, the HER2 gene can also undergo primary mutations—mutations that are consistent with those observed in secondary resistance mechanisms. The HER2 point mutations identified to date include: G309A, L755S, del755–759, D769H, D769Y, V777L, P780ins, V842I, and R896C. Cell line studies have demonstrated that all of the aforementioned mutations are sensitive to neratinib, a drug currently undergoing clinical trials.

Regarding safety, gastrointestinal toxicities—such as diarrhea—remain the most common adverse reactions associated with neratinib; however, these treatment-related adverse reactions are manageable. Diarrhea is generally non-severe and reversible; instances of severe diarrhea typically occur early in the treatment course, are of short duration, and do not lead to serious complications. Furthermore, the use of prophylactic pretreatment strategies can improve tolerability and reduce both the incidence and duration of severe diarrhea.

Study results also indicate that, beyond breast cancer, neratinib demonstrates significant therapeutic efficacy in patients with HER2-mutated non-small cell lung cancer, cervical cancer, biliary tract tumors, and salivary gland tumors. In these patient populations, tumor shrinkage exceeding 30% has been observed, and in some cases, complete tumor remission has been achieved.

Compared to so-called "generic" drugs of unclear origin—even those with active ingredient concentrations similar to those of Beacon products—significant discrepancies exist regarding critical parameters such as dissolution rate and bioavailability (factors that directly influence drug absorption). This disparity arises from the lack of strictly regulated, GMP-compliant manufacturing facilities and rigorous government oversight associated with such products.

To ensure patient safety, we urge you to exercise caution and prudence when selecting your medication.

**Indications:**

Indicated for patients with breast cancer who have completed standard adjuvant trastuzumab (Herceptin) therapy, whose disease has not progressed, but who possess high-risk factors.

**Dosage and Administration:**

The recommended dose is 240 mg (6 tablets), taken orally once daily with food, for a duration of one year.

Prior to initiating neratinib treatment, loperamide should be administered prophylactically for 56 days to prevent severe diarrhea.

**Use in Specific Populations:**

Women who are breastfeeding or lactating should discontinue the use of neratinib. Common Side Effects:

Diarrhea is a common side effect of neratinib; other common side effects include nausea, abdominal pain, fatigue, vomiting, rash, swelling, stomatitis (inflammation of the mouth), decreased appetite, muscle spasms, indigestion, and others.

Loperamide treatment should be initiated during the 56 days prior to starting neratinib therapy to prevent or mitigate diarrhea. Clinically, additional antidiarrheal medications, fluids, and electrolytes may also be administered to assist in managing diarrhea.

Manufacturer Profile:

Drug International Ltd. (DIL)—also known as Yao Pin International—is a well-established pharmaceutical company based in Bangladesh. It stands as one of Bangladesh's largest pharmaceutical enterprises and a prominent national industry leader. Founded in 1980 by Dr. M.M. Amjad Hussain, DIL emerged during an era when Bangladesh's economy was underdeveloped and poverty was widespread. Since its inception, the company has made immense contributions to the health and well-being of countless Bangladeshi citizens through a philosophy characterized by a low-profile approach and cost-effective operations. Driven by this corporate ethos of benefiting both the nation and its people, DIL rose to become Bangladesh's third-largest manufacturer of pharmaceutical raw materials in 1997. The company has consistently maintained its standing among Bangladesh's most renowned pharmaceutical firms and serves as a partner to Novartis—one of the world's top three pharmaceutical companies. The DIL Group encompasses a diverse portfolio of assets, including three large-scale pharmaceutical manufacturing plants, a biopharmaceuticals facility, a health supplements factory, an oncology research and development center, the Khwaja Yunus Ali Medical College, tea estates, garment manufacturing operations, ceramics production, printing facilities, and a software development firm. Operating in over 70 countries worldwide, the company's product line spans everything from medical devices to a wide array of finished pharmaceutical products, currently comprising a portfolio of more than 500 distinct medications.